Tiziana Life Sciences Announces Purchase of Shares by Executive Chairman

Tiziana Life Sciences (Nasdaq: TLSA) reported that Executive Chairman and founder Gabriele Cerrone, via Panetta Partners, purchased 15,000 common shares at $1.11 per share.

Rhea-AI Summary

Tiziana Life Sciences (Nasdaq: TLSA) reported that Executive Chairman and founder Gabriele Cerrone, via Panetta Partners, purchased 15,000 common shares at $1.11 per share. This transaction increased his total holding to 44,772,230 shares, representing 34.89% of Tiziana's issued share capital.

Positive

• Executive chairman buys 15,000 TLSA shares at $1.11 each
• Gabriele Cerrone’s stake increases to 44,772,230 shares
• Executive chairman now holds 34.89% of issued share capital

Negative

• None.

Argus Jun 15 session

+0.91% close to close Open Argus

Details

News Market Reaction – TLSA

On Jun 15, the day this news came out, TLSA closed 0.91% above the previous close.

Data tracked by StockTitan Argus for the Jun 15 session.

Market Context

This announcement highlights increased insider alignment, with the Executive Chairman purchasing 15,...

Analysis

This announcement highlights increased insider alignment, with the Executive Chairman purchasing 15,000 shares at $1.11, bringing his holdings to 44,772,230 shares, or 34.89% of the company. Set against recent clinical progress for intranasal foralumab and a 2025 net loss of $18.4 million, investors may weigh confidence from insider ownership against the company’s funding needs and execution risk. Key metrics to watch include upcoming Phase 2 data, additional regulatory filings, and any future capital-raising activities.

Key Figures

Insider purchase size: 15,000 shares Purchase price: $1.11 per share Total holdings: 44,772,230 shares +1 more

Insider purchase size

15,000 shares

Shares bought by Executive Chairman at $1.11 per share

Purchase price

$1.11 per share

Price paid for 15,000 newly purchased common shares

Total holdings

44,772,230 shares

Executive Chairman’s total common share holding after purchase

Ownership percentage

34.89% of issued share capital

Executive Chairman’s post-transaction ownership stake

Historical Context

5 past events · Latest: May 28

5 events

1. May 28

   Conference participation

   24h Move

   -0.7%

   Announcement of corporate presentation at Jefferies Global Healthcare Conference.

2. May 21

   Trial enrollment update

   24h Move

   -9.3%

   Full enrollment of 48 patients in INFORM-MS Phase 2a MS trial.

3. May 19

   Clinical data update

   24h Move

   +4.0%

   Updated EAP data showing tolerance and fatigue improvement trends in 14 MS patients.

4. May 14

   Imaging data readout

   24h Move

   -3.3%

   Initial Phase 2 PET imaging data in MSA showing reduced neuroinflammatory activity.

5. Apr 16

   Preclinical data

   24h Move

   +0.8%

   Positive Long COVID mouse data linking intranasal anti-CD3 to improved cognition.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

immunomodulation, anti-cd3, monoclonal antibody

3 terms

immunomodulation medical

"a biotechnology company developing breakthrough immunomodulation therapies with its lead..."

Immunomodulation is the intentional changing of the immune system’s activity—either ramping it up, calming it down, or redirecting it—to treat disease or prevent harmful reactions. Think of it like adjusting a thermostat for the body’s defenses: the goal is to achieve the right balance so patients heal without excessive inflammation or infection risk. For investors, immunomodulation matters because therapies in this area can address many diseases, carry regulatory and safety considerations, and often determine commercial potential and clinical risk.

anti-cd3 medical

"intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announces..."

An anti‑CD3 is an antibody drug that binds to the CD3 protein on T cells, the immune system’s frontline soldiers, to change how those cells behave. Think of it like attaching a remote control to specific immune cells to dial their activity up, down or redirect them; for investors, anti‑CD3 therapies signal a drug class with significant promise in autoimmune diseases, transplant protection and certain cancer strategies, but also carry clinical, regulatory and safety risks that strongly influence valuation and trial outcomes.

monoclonal antibody medical

"intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announces..."

A monoclonal antibody is a laboratory-made protein designed to recognize and attach to a specific target in the body, such as a disease-causing substance or cell. It functions like a highly precise lock-and-key tool, helping to treat or detect illnesses. For investors, companies developing monoclonal antibodies can represent promising opportunities in the healthcare sector, especially as these treatments often address unmet medical needs.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BOSTON, June 15, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announces that its Executive Chairman and Founder, Mr. Gabriele Cerrone, through Panetta Partners Ltd, an entity in which he has a beneficial interest, has increased his holdings with the purchase of 15,000 common shares at $1.11 per share, bringing his total holding to 44,772,230 common shares, which is 34.89% of issued share capital.

About Foralumab

Foralumab, a fully human anti-CD3 monoclonal antibody, is a biological drug candidate that has been shown to stimulate T regulatory cells when dosed intranasally. At present, 14 patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) have been dosed in an open-label intermediate sized Expanded Access (EA) Program (NCT06802328) with either an improvement or stability of disease seen within 6 months in all patients. In addition, intranasal foralumab is currently being studied in a Phase 2a, randomized, double-blind, placebo-controlled, multicenter, dose-ranging trial in patients with non-active secondary progressive multiple sclerosis (NCT06292923).

Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) currently in clinical development. Immunomodulation by intranasal foralumab represents a novel avenue for the treatment of neuroinflammatory and neurodegenerative human diseases.^[1],[2]

About Tiziana Life Sciences

Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana’s innovative intranasal approach has the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana’s lead candidate, intranasal foralumab, which is the only fully human anti-CD3 mAb currently in clinical development, has demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana’s technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.

For more information about Tiziana Life Sciences and its innovative pipeline of therapies, please visit www.tizianalifesciences.com.

For further inquiries:

Tiziana Life Sciences Ltd
Paul Spencer, Business Development, and Investor Relations
+44 (0) 207 495 2379
email: info@tizianalifesciences.com

[1] https://www.pnas.org/doi/10.1073/pnas.2220272120

[2] https://www.pnas.org/doi/10.1073/pnas.2309221120

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider share purchase did Tiziana Life Sciences (NASDAQ: TLSA) announce on June 15 2026?

Tiziana Life Sciences announced that Executive Chairman Gabriele Cerrone bought 15,000 TLSA common shares at $1.11 per share. According to Tiziana, the purchase was made through Panetta Partners, an entity in which he has a beneficial interest.

How many Tiziana Life Sciences (TLSA) shares does Gabriele Cerrone now own after the June 2026 purchase?

After the June 2026 transaction, Gabriele Cerrone holds 44,772,230 Tiziana Life Sciences common shares. According to Tiziana, this updated position reflects the additional 15,000 shares acquired at $1.11 per share through Panetta Partners.

What percentage of Tiziana Life Sciences’ issued share capital does Gabriele Cerrone hold after buying more TLSA shares?

Following the latest purchase, Gabriele Cerrone owns 34.89% of Tiziana Life Sciences’ issued share capital. According to Tiziana, this percentage is based on his total holding of 44,772,230 common shares after acquiring 15,000 additional shares.

At what price were the additional Tiziana Life Sciences (TLSA) shares bought by the executive chairman?

The additional TLSA shares were bought at a price of $1.11 per share. According to Tiziana, Executive Chairman Gabriele Cerrone acquired 15,000 common shares at this price through Panetta Partners, increasing his overall ownership stake.

Who purchased additional Tiziana Life Sciences (TLSA) shares through Panetta Partners in June 2026?

Executive Chairman and founder Gabriele Cerrone purchased additional Tiziana Life Sciences shares through Panetta Partners. According to Tiziana, he has a beneficial interest in Panetta Partners, which bought 15,000 TLSA common shares at $1.11 per share.

How does the June 2026 insider purchase affect ownership concentration in Tiziana Life Sciences (TLSA)?

The June 2026 purchase increases Gabriele Cerrone’s ownership to 34.89% of issued share capital. According to Tiziana, his total holding is now 44,772,230 common shares following the acquisition of 15,000 additional TLSA shares.